Can a new drug boost chemotherapy for a rare cancer?
NCT ID NCT07720193
First seen Jul 22, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This phase III trial is testing whether adding an experimental drug called LBL-024 to standard chemotherapy can help people with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC), a rare and aggressive cancer. Participants will receive either LBL-024 or a placebo alongside etoposide and cisplatin or carboplatin. The study aims to see if the combination improves overall survival compared to chemotherapy alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental drug called LBL-024 combined with standard chemotherapy (etoposide plus cisplatin or carboplatin)
- What this could lead to
- If it works, this could offer a new first-line treatment option for people with advanced extrapulmonary neuroendocrine carcinoma, potentially improving survival.
- What could go wrong
- This is an early-phase trial, so the drug may not prove more effective than chemotherapy alone. Side effects from the combination could also be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED EXTRAPULMONARY NEUROENDOCRINE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Beijing GoBroad Hospital
Beijing, Beijing Municipality, 100070, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
First Hospital of Shanxi Medical University
Taiyuan, Shanxi, 30012, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, 530200, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150081, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Henan Cancer Hospital
Zhengzhou, Henan, 450003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shandong Cancer Hospital
Jinan, Shandong, 250117, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, 030013, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sichuan Provincial People's Hospital
Chengdu, Sichuan, 610072, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Henan University of Science & Technology
Luoyang, Henan, 471023, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, 710061, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital,Sun Yat-sen University
Guangzhou, Guangdong, 510062, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yunnan Cancer Hospital
Kunming, Yunnan, 650118, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.